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Abstract: Background and aim: Cancer is the second leading cause of death globally. Nutritional status 
(cachexia) and systemic inflammation play a significant role in predicting cancer outcome. The aim 
of the present review was to examine the relationship between imaging-based body composition 
and systemic inflammation in patients with cancer. Methods: MEDLINE, EMBASE, Cochrane 
Library and Google Scholar were searched up to 31 March 2019 for published articles using MESH 
terms cancer, body composition, systemic inflammation, Dual energy X-ray absorptiometry 
(DEXA), magnetic resonance imaging (MRI), ultrasound sonography (USS) and computed 
tomography (CT). Studies performed in adult patients with cancer describing the relationship 
between imaging-based body composition and measures of the systemic inflammatory response 
were included in this review. Results: The literature search retrieved 807 studies and 23 met the final 
eligibility criteria and consisted of prospective and retrospective cohort studies comprising 11,474 
patients. CT was the most common imaging modality used (20 studies) and primary operable (16 
studies) and colorectal cancer (10 studies) were the most commonly studied cancers. Low skeletal 
muscle index (SMI) and systemic inflammation were consistently associated; both had a prognostic 
value and this relationship between low SMI and systemic inflammation was confirmed in four 
longitudinal studies. There was also evidence that skeletal muscle density (SMD) and systemic 
inflammation were associated (9 studies). Discussion: The majority of studies examining the 
relationship between CT based body composition and systemic inflammation were in primary 
operable diseases and in patients with colorectal cancer. These studies showed that there was a 
consistent association between low skeletal muscle mass and the presence of a systemic 
inflammatory response. These findings have important implications for the definition of cancer 
cachexia and its treatment. 
Keywords: body composition; computed tomography; dual energy X-ray absorptiometry; 
ultrasound; magnetic resonance imaging; systemic inflammation; cancer; cachexia 
 
1. Introduction 
Cancer is the second leading cause of death and has resulted in 9.6 million deaths worldwide in 
2018 [1]. Patients present with various stages of cancers and the treatment aim is usually classified as 
curative or palliative, depending on the stage of the disease and patient factors (performance status, 
co-morbidities). The decision-making process for each patient is complex and involves 
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multidisciplinary team discussions; moreover, using the optimal therapy in the correct patients 
improves quality of life and survival and has positive implications for health care resources. 
As cancer progresses, it is frequently associated with anorexia, weight loss and loss of skeletal 
muscle mass (termed cancer cachexia) and these are known to be associated with poor outcome. The 
basis for such changes in body habitus is not clearly understood [2]. For example, some tumour types, 
such as lung and gastrointestinal cancers, are particularly associated with weight and muscle loss; 
however, in other tumour types (e.g., breast, prostate), this is less common.  
While in the past, weight loss and body mass index (BMI) have been used as indicators for 
malnutrition and cancer cachexia, there have been ongoing attempts to better define body 
composition in patients with cancer. Various techniques, such as bioelectric impedance analysis, 
whole body potassium, and air displacement plethysmography, have been used to quantify body 
composition in the research setting. More recently, imaging-based approaches, such as Dual-energy 
X-ray absorptiometry (DEXA), magnetic resonance imaging (MRI), ultrasound scan (USS) and 
computed tomography (CT), have been utilized. These imaging-based body composition measuring 
modalities have the advantage that they are readily available and would be readily adopted into 
clinical practice if shown to be clinically useful. In particular, an excellent agreement between DEXA, 
CT, and MRI for adipose tissue and skeletal muscle has been reported [3–7].  
In particular due to its routine use in cancer staging, CT has become the preferred standard for 
measuring body composition, providing useful new information on body compositional changes 
associated with cancer cachexia [3–5]. In particular, fat and muscle area at Lumbar 3 (L3) vertebra 
level is highly correlated to other measures of body composition [4,8]. A Skeletal muscle index (SMI) 
calculated from image based body composition analysis, provides a reliable objective assessment of 
skeletal muscle quantity [5]. These imaging-based modalities (DEXA,CT,MRI) have also been 
investigated in various benign diseases, such as myopathies, malnutrition, chronic respiratory, renal 
and cardiac illnesses, and these have been found to be reliable tools for the assessment of muscle 
quantity [9]. 
The basis of the disproportionate loss of skeletal muscle over adipose tissue is not clear. 
However, it now recognised that systemic inflammatory response is associated with weight and 
muscle loss and poorer outcomes in patients with cancer [10] and may be useful in identifying the 
various stages of cachexia [11] (Table 1). Therefore, the routine clinical use of radiological imaging 
offers the opportunity to examine these relationships in more detail. The present review examines 
the relationship between imaging-based body composition and systemic inflammatory response in 
patients with cancer. 
Table 1. Framework based on modified Glasgow Prognostic score (mGPS). 
mGPS Biochemical Markers Cachexia Stage 
 CRP (mg/L) Albumin (g/L)  
0 <10 ≥35 No cachexia 
0 <10 <35 Undernourished 
1 >10 ≥35 Pre-cachexia 
2 >10 <35 Refractory cachexia 
CRP = C-reactive protein. 
2. Patients and Methods 
2.1. Data Sources and Search Strategy 
A study protocol was developed in accordance to the Preferred Reporting Items for Systematic 
Review and Meta-analyses (PRISMA) guidelines [12]. A systematic search using Medline, EMBASE, 
Cochrane databases and Google Scholar was carried out to identify studies assessing the relationship 
between body composition, systemic inflammation and cancer using MESH Terms “body 
composition, computed tomography (CT), Dual Energy X-ray Absorptiometry (DEXA), Magnetic 
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resonance imaging (MRI), Ultrasound scan (USS), systemic inflammation, cancer and cachexia”. The 
search was conducted from the start of the relevant database to the date of the last search, which was 
31 March 2019. 
All relevant studies evaluating the relationship between body composition and systemic 
inflammatory response in adult patients with cancer were included. For this systematic review, 
animal studies, conference abstracts, reviews, non-English studies and those not measuring the topic 
of interest were excluded. The study titles were screened for relevance before a review of abstracts 
and full texts (TA). Discrepancies were addressed by re-examination and discussion with the senior 
author (DCM). Reference lists from relevant studies were hand-searched for any other eligible 
studies. The eligible studies were then assessed for quality using the 22-point STROBE 
(STrengthening the Reporting of OBservational studies in Epidemiology) checklist, which is a 
validated methodological quality assessment tool used for submitting studies and to provide 
feedback by reviewers [13]. 
3. Results 
Initially, 807 studies were identified, and following subsequent screening of titles, abstracts and 
then full papers, 23 met the final eligibility criteria (Figure 1). Articles were excluded if there was no 
relationship studied between body composition and systemic inflammation (n = 192), animal studies 
(n = 141), duplicates (n = 17), non-cancerous (n = 16), full articles not available (n = 3) and those that 
were reviews only (n = 2). Another 411 studies were excluded following review, as they did not 
address the topic of interest, namely the relationship between imaging-based body composition and 
systemic inflammation in patients with cancer. 
No study examining the relationship between MRI and USS-derived body composition analysis 
and markers of the systemic inflammatory response was identified. There were three studies that 
examined the relationship between DEXA-derived body composition analysis and markers of the 
systemic inflammatory response and 20 studies that examined this relationship with CT-derived 
body composition analysis. Of the 20 CT studies, 19 reported body composition analysis using the L3 
level of the vertebral column. 
 
Figure 1. Preferred reporting items for systematic review protocol flow diagram. 
All DEXA studies [14–16] included in this review used LUNAR DPX-L & LUNAR PRODIGY 
software (Discovery®, Hologic, Bedford, MA USA) for body composition measurements. Of the 20 
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CT studies, six studies [17–22] used Slice-O-Matic software ( TomoVision, Montreal, Quebec, 
Canada), three studies [23–25] used Image J software (NIH Image J version 1.47, 
https://imagej.nih.gov/ij/), two studies [26,27] used Synapse Vincent software ( Fujifilm Medical, 
Tokyo, Japan), two studies [28,29] used Infinitt PACS software ( INFINITT Healthcare Co., Ltd, Seoul, 
Korea), one study [30] used OSIRIX software (OSIRIX ®, Version 3.3, downloaded from 
http://www.osirix-viewer.com), one study [31] used Terrarecon software (Terarecon 3.4.2.11, San 
Mateo, CA, USA), one study [32] used Somatom Software (Somatom Sensation, Siemens, Fairfield, 
CT, USA) and manual CT images analyses was performed in four studies [33–36]. All the 20 CT 
studies used same thresholds for muscle (−29 to 150 HU) to measure SMA, which were normalized 
for height 2 to define SMI. Irving et al. compared Slice-O-Matic with Image J in 26 obese subjects with 
intra- and inter-investigator co-efficient with a reliability of R2 = 0.99 and a mean difference of less 
than 2% [37], Richards et al. compared Slice-O-Matic and Image J in a sample of 50 cases with a mean 
difference of 7.50 cm2 [23], Van Vugt et al. compared four software packages (Image J, sliceOmatic, 
OsiriX and FatSeg) in a sample of 50 cases with inter-software an intra-class correlation coefficient of 
(≥0.999) and a p-value of <0.001 [38], and Teigen et al. compared Slice-O-Matic with Image J in 51 
cases with an overall mean difference of 1.53cm2 [39]. Therefore, it appears that there was excellent 
agreement between the most commonly used software packages. As a result, the study cohorts were 
considered together in the present review. 
Using the STROBE checklist, the breakdown of quality of these studies is given in Table 2. The 
lowest score achieved was 16 [32] and the highest was 20 (multiple). Length of follow up was a 
variable. The characteristics of the included studies, the relationship between imaging-based body 
composition and systemic inflammation are summarized in Table 2. The measurement of body 
composition was carried out in three studies using DEXA and in 20 studies using CT. Therefore, 23 
studies met the final inclusion criteria, with 11,474 cancer patients studied (6281 males and 5193 
females). 
The majority of the studies were single centre (20 studies, n = 8,785), prospective (12 studies, n = 
8,611) and carried out in European countries (12 studies, n = 3,272). There were seven studies carried 
out in Asian countries (n = 2,362) and four studies in the USA (n = 5,840). The majority of studies were 
in primary operable cancer (16 studies, n = 10,198) and colorectal cancer was the most commonly 
studied cancer (10 studies, n = 8,344). 
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Table 2. Characteristics of included studies. 
Authors (Year) 
Reported 
STROBE 
Checklist 
Points 
Type of Study n (F/M) Country Cancer Studied Cancer Stage Level of 
Analysis 
Systemic 
Inflammation 
Comments 
DEXA          
Ellega°rd et al, 
2009 [14] 
20 
Prospective 
cross-sectional 
132 (46/86) 
Sweden & 
New Zealand 
Gastrointestinal  
Advanced 
inoperable 
Whole 
body 
CRP, 
Albumin 
Low SMI directly associated with 
elevated CRP and low albumin (p < 
0.05). 
Wallengren et 
al, 2014 [15] 
19 
Prospective 
longitudinal  
471 
(212/259) 
Sweden  
Gastrointestinal, 
pancreatic-
biliary  
Advanced 
inoperable 
Whole 
body 
CRP, 
Albumin 
Low SMI directly associated with 
elevated CRP (p < 0.001). 
Chambard et 
al, 2018 [16] 
20 
Prospective 
cross-sectional 
64 (16/48) France 
Non-small cell 
Lung 
Advanced 
inoperable 
Whole 
body 
CRP, 
Albumin, 
WCC 
Low SMI directly associated with 
elevated CRP (p < 0.05) & WCC (p < 
0.001). 
CT          
Richards et al, 
2012 [23] 20 
Prospective 
cross-sectional 174 (79/95) 
United 
Kingdom Colo-rectal 
Primary 
operable L3 
CRP, 
Albumin, 
mGPS, NLR 
Low SMI (34%) directly associated 
with elevated mGPS (32%) (p < 0.001)  
Itoh et al, 2013 
[33] 
19 
Retrospective 
cross-sectional 
190 (44/146) Japan Hepatocellular  
Primary 
operable 
L3 Albumin 
Low visceral fat area associated with 
sarcopenia (p < 0.001) and low albumin 
(p < 0.005) 
Reisinger et 
al,2016 [30] 
17 
Prospective 
cross-sectional 
87 (31/56) Netherlands Colo-rectal 
Primary 
operable 
L3 CRP, mGPS 
Low SMI associated with elevated CRP 
(p = 0.05). 
Rollins et, 
al,2016 [17] 
18 
Retrospective 
cross-sectional 
229 
(105/124) 
United 
Kingdom 
Pancreatic-
biliary  
Advanced 
inoperable 
L3 
CRP, 
Albumin, 
mGPS, NLR 
Low SMI and SMD associated with 
elevated CRP (p < 0.05), low albumin (p 
< 0.001) and elevated NLR (p < 0.01). 
Malietz et al, 
2016 [19] 
19 
Prospective 
longitudinal 
763 
(306/457) 
United 
Kingdom 
Colo-rectal 
Primary 
operable 
L3 
Albumin, 
NLR 
Low SMI (65%) and low SMD (84%) 
associated with NLR > 3 (61% & 57%) 
(p < 0.001) and low albumin (28% each) 
(p = 0.01). 
Kim et al, 2016 
[31] 
20 
Retrospective 
cross-sectional 
186 (30/156) South Korea Small cell lung 
Primary 
operable 
L3 
CRP, 
Albumin, 
mGPS, NLR 
Low SMI associated with elevated CRP 
(p < 0.05), low albumin (p < 0.05) and 
elevated NLR (p < 0.01). 
Zhuang et al, 
2016 [28] 
19 
Retrospective 
cross-sectional 
937 
(207/730) 
China Gastric  
Primary 
operable 
L3 Albumin 
Low SMI associated with low albumin 
(p < 0.001). 
Huang, et al, 
2016 [29] 
20 
Prospective 
cross-sectional 
470 
(364/106) 
China Gastric 
Primary 
operable 
L3 Albumin 
Low SMI associated with low albumin 
(p < 0.001). 
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Van Di Jik et al, 
2017 [18] 
19 
Prospective 
cross-sectional 
186 (84/102) Netherlands Pancreatic 
Both 
operable and 
inoperable  
L3 
CRP, 
Albumin, 
mGPS 
Low SMD associated with low 
albumin (p < 0.01) 
Feliciano et al, 
2017 (C-SCANS 
study) [20] 
20 
Retrospective 
longitudinal 
2470 
(1219/1251) 
United States, 
Canada 
Colo-rectal 
Primary 
operable 
L3 
CRP, 
Albumin, 
NLR, IL-6 
Low SMI associated with elevated CRP 
(p < 0.05), low albumin (p < 0.01) and 
elevated IL-6 (p < 0.05) 
Srdic et al, 2017 
[34] 
20 
Prospective 
cross-sectional 
100 (33/67) Croatia 
Non-small cell 
lung 
Advanced 
inoperable 
L3 
CRP, 
albumin, 
mGPS 
Low SMI (15% loss of skeletal muscle 
mass) associated with low albumin (p < 
0.01) 
Kiyotoki et al, 
2017 [26] 
20 
Retrospective 
cross-sectional 
60 
All females 
Japan Cervical 
Primary 
operable 
L3 
CRP, 
Albumin  
Low SMI associated with low albumin 
(p < 0.01). 
Serra et al, 2017 
[32] 
16 
Prospective 
cross-sectional 
11 
All females 
United States Breast  
Primary 
operable 
L4-L5 
CRP, 
Albumin 
Significant improvement in muscle 
strength with resistance training with 
reduction in inflammatory mediators 
including CRP. 
McSorley et al, 
2017 [24] 
20 
Retrospective 
cross-sectional 
322 
(148/174) 
United 
Kingdom 
Colo-rectal 
Primary 
operable 
L3 
CRP, 
Albumin, 
mGPS, NLR 
Low SMI (47%) and SMD (58%) 
associated with elevated mGPS (23%) 
and NLR > 3 (44%) (p < 0.01). 
Van DiJik et 
al,2018 [21] 
20 
Prospective 
cross-sectional 
97 (30/67) Canada Colo-rectal 
Primary & 
metastatic 
both 
operable 
L3 
CRP, 
Albumin 
Low SMI (65%) associated with 
elevated CRP > 5 mg/dL (74%) (p < 
0.05).  
Okugawa et al, 
2018 [35] 
20 
Prospective 
cross-sectional 
308 
(125/183) 
Japan Colo-rectal 
Primary 
operable 
L3 
CRP, 
Albumin, 
NLR, PLR 
Low SMI and SMD associated with 
elevated CRP (p < 0.0001) and low 
albumin (p < 0.05). 
Dolan et al, 
2018 [25] 
19 
Retrospective 
cross-sectional 
650 
(296/354) 
United 
Kingdom 
Colo-rectal 
Primary 
operable 
L3 
CRP, 
Albumin, 
mGPS, NLR 
Low SMI (44%) and SMD (60%) 
associated with elevated mGPS (23%) 
(p < 0.001) and NLR > 3 (43%) (p < 0.05). 
Sueda et al, 
2018 [27] 
20 
Retrospective 
cross-sectional 
211 (77/134) Japan Colo-rectal 
Primary 
operable 
L3 
Albumin, 
NLR 
Low SMI (48%) and SMD (49%) 
associated with NLR > 3 (41%) with (p 
< 0.05) and p < 0.01 respectively. 
Basile et al, 
2019 [36] 
20 
Retrospective 
longitudinal  
94 (42/52) Italy Pancreatic  
Advanced 
inoperable 
L3 
CRP, 
Albumin, 
NLR 
Low SMI & SMD associated with NLR 
> 5(p < 0.001).  
Xiao et al, 2019 
[22] 
20 
Retrospective 
cross-sectional 
3262 
(1628/1624) 
United States Colo-rectal 
Primary 
Operable 
L3 
CRP, 
Albumin, 
NLR 
Low SMI & SMD associated with 
raised NLR ≥ 5 (p < 0.001). 
L3 = Lumbar 3 vertebral level, SM I= Skeletal muscle index, SMD = Skeletal muscle density, mGP S= modified Glasgow prognostic score, NLR = Neutrophil 
lymphocyte ratio 
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The skeletal muscle index (SMI) was most commonly measured (21 studies, n = 11,277) and C-
reactive protein (CRP) and albumin were the most commonly measured markers of the systemic 
inflammatory response (18 studies, n = 8903 and 23 studies, n = 11,474 respectively). A significant 
inverse relationship between SMI and CRP was reported in 13 studies (n = 5201), a significant inverse 
relationship between SMI and mGPS (combination of CRP and albumin) was reported in eight  
studies (n = 1934), a significant inverse relationship between SMI and NLR was reported in eight 
studies (n = 5717) and a direct relationship between SMI and albumin in 15 studies (n = 7002). 
A low SMI was reported to be associated with shorter overall survival (10 studies, n = 5202) and 
associated with shorter overall survival independent of markers of the systemic inflammatory 
response (seven studies, n = 4481). When both sarcopenia and systemic inflammation were combined, 
the risk of death was doubled [20]. 
Low skeletal muscle density (SMD) and its relationship to systemic inflammation was reported 
in nine studies (n = 6025). A significant inverse relationship between SMD and NLR was reported in 
seven studies (n = 5531), a significant inverse relationship between SMD and mGPS in four studies (n 
= 1509) and a direct relationship between SMD and albumin in six studies (n = 1906). A low SMD was 
reported to be associated with decreased overall survival in four studies (n = 1412), cancer-specific 
survival in two studies (n = 533) and disease-free survival in one study (n = 211).  
A total of 19 of 23 studies were cross-sectional cohort studies. Four studies were longitudinal 
cohort (1 in DEXA[15] and three in the CT group [19,20,36]). A significant inverse relationship 
between SMI and CRP was reported in two longitudinal studies (n = 2941), and an inverse 
relationship between SMI and NLR in two longitudinal studies (n = 857) and a direct relationship 
between SMI and albumin in three longitudinal studies (n = 3704). 
4. Discussion 
The results of the present systematic review show that in approximately 10,000 patients with 
cancer, there was a consistent association between CT-derived SMI/SMD and systemic inflammation, 
as evidenced by CRP, albumin (mGPS) and Neutrophil Lymphocyte Ratio (NLR). To our knowledge, 
this is the first such systematic review. Since this relationship was determined mainly in cross-
sectional studies and in primary operable cancers, it is not clear whether a low SMI/SMD results in 
the presence of systemic inflammation or whether the presence of systemic inflammation results in 
low SMI/SMD. Nevertheless, given the importance of these respective measures in defining the 
syndrome of cancer cachexia and cancer progression, it is important to examine this relationship in 
more detail, particularly in patients with advanced cancer [10,11,40,41]. CT abdomen is part of cancer 
staging in patients with a wide variety of cancers, including gastrointestinal, hepato-biliary, 
pancreatic, renal, bladder and lung cancers. From CT abdomen, the L3 level can be readily calculated  
using manual or semi-automated software packages and  using muscle and adipose tissue thresholds, 
all components of body composition can be calculated.  
However, the clinical utility of landmarks other than L3 is not clear. There is some debate as to 
whether the measurement of psoas muscle at lumbar 3 level is less reliable and inferior to measuring 
all muscles at this level [42,43] and therefore, these studies [44,45] were considered separately. Using 
psoas muscle measurement, Hervochon and co-workers, in a cohort of 161 patients with operable 
NSCLC, reported that low SMI (total psoas area ≤ 33rd percentile) was significantly associated with 
elevated CRP [44]. Furthermore, Okugawa and co-workers, in a cohort of 308 patients with operable 
CRC, reported that low SMI (using sex-specific median values of psoas muscle index, male: 286.8 
mm2/m2, female: 210.6 mm2/m2) was significantly associated with elevated CRP and low albumin [45]. 
Therefore, it would appear that skeletal muscle, however, assessed from CT scans, is consistently 
associated with measures of the systemic inflammatory response. 
Since there is little evidence that increasing skeletal muscle mass is associated with a reduction 
in cancer-associated systemic inflammation, a plausible hypothesis explaining this relationship is that 
a pro-inflammatory state is the main etiological factor in progressive muscle loss and this underpins 
the nutritional and functional decline associated with cancer cachexia. For example, comparing 
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inoperable cancer with operable cancer, the former is consistently associated with greater tumour 
bulk and greater elevation of the mGPS and NLR [40,41] and weight and skeletal muscle loss is a 
feature of the cachexia of advanced disease. Furthermore, a greater elevation of the mGPS is 
associated with more aggressive tumours, such as lung and pancreatic cancer [40,46,47], and these 
tumours are characterized as the tumour types most commonly associated with cachexia. 
Therefore, it is of interest that there is good evidence that elevated circulating concentrations of 
key pro-inflammatory cytokines (e.g., Interleukin 6 [IL-6], Interleukin 1 [IL-1]) link the presence and 
aggressiveness of the tumour to the loss of skeletal muscle mass [48,49] and elevated markers of the 
systemic inflammatory response [50]. If this was the case, the pro-inflammatory state could be 
expected to be a catabolic event and would predate the significant loss of skeletal muscle mass. 
Indeed, of the longitudinal studies reviewed, the presence of a systemic inflammatory response at 
baseline was associated with lower SMI on follow-up independent of tumour stage in patients with 
primary operable cancer [19,20]. Furthermore, it is recognized that an elevated CRP and low albumin 
concentration are risk factors for the development of cancer [51,52]. Taken together, these 
observations directly link the loss of skeletal muscle mass and the presence of a systemic 
inflammatory response. If this hypothesis were to prove to be the case, it would have profound 
implications for how cachexia is defined and how it is treated in cancer patients. 
With reference to the definition of cancer cachexia, it has been currently defined as weight loss 
> 5% or BMI < 20kg/m2 with weight loss > 2% or sarcopenia with weight loss > 2% [53]. However, the 
present review and the above rationale make a powerful argument for the definition of cancer 
cachexia to be based on the presence of a systemic inflammatory response, the mGPS, given its 
consistent thresholds [10]. This can be clarified using a quote by MacDonald in his 2012 review article. 
‘The seminal observation by McMillan and colleagues that the presence of dysregulated state as 
evidenced by a high CRP connotes a dire prognosis has generally been ignored to date and not used 
to stratify patients in oncology clinical trials. Particularly in the more aggressive tumour types (e.g. 
pancreas and lung), the future of patients with elevated mGPS is so grim that they should be given 
precachexia status and offered multimodal therapy which may delay the onset of cachexia and/ or 
death [47].’ More recently, Baracos et al, proposed that the cardinal feature of cachexia was the loss 
of skeletal muscle [54]. Given that the systemic inflammatory response is a major driver of this loss 
(supported by the present review), it can readily be argued that the systemic inflammatory response 
forms the basis of definition of cancer cachexia. Indeed, there is increasing data to support such an 
approach [55]. Clearly in light of the present review, the systemic inflammation may be combined 
with a low SMI [25] and/ or combined with performance status [56,57] to better define cachexia. 
With reference to the treatment of cancer cachexia, the present review suggests that systemic 
inflammatory response should be primarily targeted. Unfortunately, to date, few attempts have been 
made to use systemic inflammation as a therapeutic end-point [58]. More recently, an early phase 
clinical trial using a multimodal intervention with an anti-inflammatory agent (Ibuprofen, 
Trondheim, Norway) had a positive effect on the weight and lean body mass and this is now being 
examined in a phase 3 trial (Trial registration number NCT02330926) in advanced cancer patients 
[59]. Using a more potent anti-inflammatory, another randomized controlled trial is underway, using 
bermekimab, which is a humanized antibody to IL-1α [49] and examining its effects on muscles, 
physical function and appetite in patients with lung, pancreatic or ovarian cancer (MICA trial). If 
anti-inflammatory treatment given to patients that had evidence of a systemic inflammatory response 
were proven to prevent further loss of skeletal muscle, this would be a major step forward for the 
definition and treatment of patients with cancer cachexia.  
A potential management algorithm is shown in Figure 2. On the CT staging of the tumour, there 
should also be assessment of body composition and laboratory assessment of the systemic 
inflammatory response. In particular, assessment of SMI and mGPS should be carried out. Such 
staging of the tumour and host would provide the basis for patient optimization, providing 
nutritional support and anti-inflammatory agents [60]. 
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Figure 2. Management algorithm of pre-treatment assessment in patients with cancer. SMA = Skeletal 
muscle area, SMI = Skeletal muscle index, SMI = Skeletal muscle density, mGPS = modified Glasgow 
prognostic score, NLR = neutrophil lymphocyte ratio. 
This systematic review has some limitations. Firstly, included studies were mainly retrospective 
and cross sectional. Secondly, the studies were heterogeneous, with various markers of systemic 
inflammation across a range of various cancers. Thirdly, most of the studies were from single 
institutions. Large prospective multi-centre follow-up studies involving collaborations among 
researchers, clinicians, dieticians, physiotherapists, nurses and the pharmaceutical industry are 
required to generalize the findings of this systematic review and to provide the best patient care. 
Moreover, how an algorithm could be routinely incorporated into standard radiological imaging 
software to capture SMI and SMD for clinical reporting remains to be established. At present, it is not 
clear whether muscle loss from cancer can be differentiated from purposeful weight loss using CT. 
5. Conclusion 
The present systematic review shows low SMI and low SMD to be consistently associated with 
measures of systemic inflammatory response, including CRP, albumin, mGPS and NLR, in patients 
with cancer. These observations have implications for the definition and treatment of cancer cachexia 
which should include measures of the systemic inflammatory response. Once the technical hurdles 
can be overcome, reporting of SMI should be considered as a routine part of radiology reporting 
because of its clinical significance. 
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